CN102573917B - 聚乙二醇化的l-天冬酰胺酶 - Google Patents
聚乙二醇化的l-天冬酰胺酶 Download PDFInfo
- Publication number
- CN102573917B CN102573917B CN201080030392.6A CN201080030392A CN102573917B CN 102573917 B CN102573917 B CN 102573917B CN 201080030392 A CN201080030392 A CN 201080030392A CN 102573917 B CN102573917 B CN 102573917B
- Authority
- CN
- China
- Prior art keywords
- asparaginase
- conjugate
- peg
- erwinia
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22332009P | 2009-07-06 | 2009-07-06 | |
| US61/223,320 | 2009-07-06 | ||
| PCT/EP2010/054156 WO2011003633A1 (en) | 2009-07-06 | 2010-03-30 | Pegylated l-asparaginase |
| EPPCT/EP2010/054156 | 2010-03-30 | ||
| PCT/EP2010/059599 WO2011003886A1 (en) | 2009-07-06 | 2010-07-06 | Pegylated l-asparaginase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102573917A CN102573917A (zh) | 2012-07-11 |
| CN102573917B true CN102573917B (zh) | 2015-06-17 |
Family
ID=42232655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080030392.6A Active CN102573917B (zh) | 2009-07-06 | 2010-07-06 | 聚乙二醇化的l-天冬酰胺酶 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US20120100121A1 (enExample) |
| JP (1) | JP6014956B2 (enExample) |
| KR (1) | KR101731999B1 (enExample) |
| CN (1) | CN102573917B (enExample) |
| AU (1) | AU2010270294B2 (enExample) |
| BR (1) | BR112012000367A2 (enExample) |
| CA (1) | CA2767149C (enExample) |
| CO (1) | CO6612174A2 (enExample) |
| DK (1) | DK2451486T4 (enExample) |
| EA (1) | EA021168B1 (enExample) |
| ES (1) | ES2636476T5 (enExample) |
| FI (1) | FI2451486T4 (enExample) |
| HU (1) | HUE035771T2 (enExample) |
| IL (1) | IL217392A (enExample) |
| IN (1) | IN2012DN00958A (enExample) |
| LT (1) | LT2451486T (enExample) |
| MA (1) | MA33503B1 (enExample) |
| MX (1) | MX2012000424A (enExample) |
| MY (1) | MY180758A (enExample) |
| NZ (1) | NZ597912A (enExample) |
| PE (2) | PE20161325A1 (enExample) |
| PT (1) | PT2451486T (enExample) |
| SG (1) | SG176984A1 (enExample) |
| UA (1) | UA104634C2 (enExample) |
| WO (2) | WO2011003633A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE531779C2 (sv) * | 2007-11-26 | 2009-08-04 | Promimic Ab | Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer |
| WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
| WO2015038639A1 (en) * | 2013-09-10 | 2015-03-19 | Sandia Corporation | Therapeutic asparaginases |
| CN104046600B (zh) | 2013-12-30 | 2019-04-05 | 江苏众红生物工程创药研究院有限公司 | 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用 |
| BR102014000585B1 (pt) | 2014-01-10 | 2021-01-12 | Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação | l-asparaginase recombinante de zymomonas |
| US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
| CN105802948B (zh) | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 |
| ES2839212T3 (es) | 2015-09-29 | 2021-07-05 | Inst Nat Sante Rech Med | Métodos para determinar el estado metabólico de linfomas B |
| CN109153711B (zh) * | 2016-03-01 | 2022-04-26 | 伊利诺伊大学理事会 | 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白 |
| PT3463308T (pt) | 2016-06-01 | 2022-03-11 | Servier Ip Uk Ltd | Formulações de óxido de polialquileno asparaginase e métodos de fabrico e utilização do mesmo |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP3535386A4 (en) * | 2016-11-04 | 2020-04-15 | Georgia State University Research Foundation, Inc. | ENDOTOXIN-FREE ASPARAGINASE |
| FI3642340T3 (fi) * | 2017-06-21 | 2024-06-18 | Jazz Pharmaceuticals Ireland Ltd | Muunneltu l-asparaginaasi |
| EP3418383A1 (en) * | 2017-06-21 | 2018-12-26 | XL-protein GmbH | Modified l-asparaginase |
| US10174302B1 (en) | 2017-06-21 | 2019-01-08 | Xl-Protein Gmbh | Modified L-asparaginase |
| JP7358347B2 (ja) | 2017-10-27 | 2023-10-10 | フェネックス インク． | 組み換えＥ．ｃｏｌｉアスパラギナーゼの製造のための方法 |
| AU2018354067B2 (en) * | 2017-10-27 | 2023-03-30 | Pfenex Inc. | Method for production of recombinant Erwinia asparaginase |
| KR20200119234A (ko) * | 2017-11-30 | 2020-10-19 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 아스파라기나제를 이용한 치료 방법 |
| EP3781197B1 (en) * | 2018-04-19 | 2025-09-10 | Elanco US Inc. | Variant asparaginase polypeptides for medical use |
| US20210299233A1 (en) | 2018-07-12 | 2021-09-30 | The Children's Medical Center Corporation | Method for treating cancer |
| EP3867369A4 (en) * | 2018-12-24 | 2022-09-14 | Gennova Biopharmaceuticals Limited | FREEZE-DRIED COMPOSITION OF PEGASPARGASE |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
| JP2022553399A (ja) * | 2019-10-25 | 2022-12-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 組換えｌ－アスパラギナーゼ |
| KR102269634B1 (ko) * | 2019-10-31 | 2021-06-25 | 대상 주식회사 | ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주 |
| CA3179177A1 (en) | 2020-12-23 | 2022-06-30 | Jazz Pharmaceuticals Ireland Ltd. | Methods of purifying charge-shielded fusion proteins |
| CN114854729B (zh) * | 2021-02-03 | 2025-09-02 | 重庆派金生物科技有限公司 | 定向化学偶联门冬酰胺酶突变体及其制备方法和应用 |
| US20220313798A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP4551216A1 (en) | 2022-07-04 | 2025-05-14 | Institut National de la Santé et de la Recherche Médicale | Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma |
| WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
| WO2024211977A1 (pt) * | 2023-04-12 | 2024-10-17 | Biobreyer Pesquisa E Desenvolvimento Científico Ltda | Processo de peguilação sítio específica de lasparaginase contendo cisteínas de superfície, produto obtido por processo e uso |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018742A2 (en) * | 2001-08-22 | 2003-03-06 | Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha Rossiiskoy Akademii Meditsinskikh Nauk | Recombinant l-asparaginase erwinia caratovora |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| GB9017002D0 (en) | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5776746A (en) | 1996-05-01 | 1998-07-07 | Genitope Corporation | Gene amplification methods |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| AU2004221824B2 (en) | 2003-03-14 | 2009-08-27 | Ratiopharm Gmbh | Branched water-soluble polymers and their conjugates |
| WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| WO2007123006A1 (ja) | 2006-04-21 | 2007-11-01 | Konica Minolta Holdings, Inc. | ガスバリアフィルム、有機エレクトロルミネッセンス用樹脂基材、それを用いた有機エレクトロルミネッセンス素子及びガスバリアフィルムの製造方法 |
| DK2851424T3 (en) * | 2007-03-09 | 2017-01-16 | Novozymes As | asparaginases |
| WO2011003633A1 (en) | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
-
2010
- 2010-03-30 WO PCT/EP2010/054156 patent/WO2011003633A1/en not_active Ceased
- 2010-07-06 WO PCT/EP2010/059599 patent/WO2011003886A1/en not_active Ceased
- 2010-07-06 JP JP2012518956A patent/JP6014956B2/ja active Active
- 2010-07-06 PE PE2016001555A patent/PE20161325A1/es unknown
- 2010-07-06 EA EA201270134A patent/EA021168B1/ru not_active IP Right Cessation
- 2010-07-06 LT LTEP10730170.7T patent/LT2451486T/lt unknown
- 2010-07-06 SG SG2011096013A patent/SG176984A1/en unknown
- 2010-07-06 CN CN201080030392.6A patent/CN102573917B/zh active Active
- 2010-07-06 MX MX2012000424A patent/MX2012000424A/es active IP Right Grant
- 2010-07-06 ES ES10730170T patent/ES2636476T5/es active Active
- 2010-07-06 MY MYPI2012000054A patent/MY180758A/en unknown
- 2010-07-06 MA MA34598A patent/MA33503B1/fr unknown
- 2010-07-06 FI FIEP10730170.7T patent/FI2451486T4/fi active
- 2010-07-06 UA UAA201201135A patent/UA104634C2/ru unknown
- 2010-07-06 KR KR1020127003202A patent/KR101731999B1/ko active Active
- 2010-07-06 PE PE2012000023A patent/PE20120501A1/es not_active Application Discontinuation
- 2010-07-06 HU HUE10730170A patent/HUE035771T2/en unknown
- 2010-07-06 BR BR112012000367A patent/BR112012000367A2/pt not_active Application Discontinuation
- 2010-07-06 US US13/382,276 patent/US20120100121A1/en not_active Abandoned
- 2010-07-06 PT PT107301707T patent/PT2451486T/pt unknown
- 2010-07-06 AU AU2010270294A patent/AU2010270294B2/en active Active
- 2010-07-06 CA CA2767149A patent/CA2767149C/en active Active
- 2010-07-06 DK DK10730170.7T patent/DK2451486T4/da active
- 2010-07-06 NZ NZ597912A patent/NZ597912A/en unknown
-
2012
- 2012-01-05 IL IL217392A patent/IL217392A/en active IP Right Grant
- 2012-02-02 IN IN958DEN2012 patent/IN2012DN00958A/en unknown
- 2012-02-06 CO CO12020409A patent/CO6612174A2/es unknown
-
2015
- 2015-08-05 US US14/819,305 patent/US9920311B2/en not_active Ceased
-
2018
- 2018-02-01 US US15/886,216 patent/US20180346900A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,764 patent/USRE49736E1/en active Active
- 2020-05-18 US US16/877,324 patent/US11046946B2/en active Active
-
2021
- 2021-06-03 US US17/338,508 patent/US12441992B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018742A2 (en) * | 2001-08-22 | 2003-03-06 | Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha Rossiiskoy Akademii Meditsinskikh Nauk | Recombinant l-asparaginase erwinia caratovora |
Non-Patent Citations (6)
| Title |
|---|
| Chemistry for peptide and protein PEGylation;ROBERTS M J et al.;《ADVANCED DRUG DELIVERY REVIEWS》;20020617;第54卷(第4期);459-476 * |
| E•coli L-天冬酰胺酶B细胞抗原表位氨基酸残基Lys~(196)对其抗原性的影响;陈建华等;《中国药科大学学报》;20061231;第37卷(第3期);277-280 * |
| Modification of recombinant asparaginase from Erwinia carotovora with polyethylene glycol 5000;A.V.KUCHUMOVA et al.;《BIOCHEMISTRY (MOSCOW) SUPPLEMENTAL SERIES B:BIOMEDICAL CHEMISTRY》;20070904;第1卷(第3期);230-232 * |
| Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past,the present and recommendations for the future;AVRAMIS VASSILIOS I et al.;《CLINICAL PHARMACOKINETICS》;20050401;第44卷(第4期);367-393 * |
| 聚乙二醇对大肠杆菌L-天冬酰胺酶的化学修饰;周笑艳等;《中国药科大学学报》;20001231;第31卷(第3期);230-233 * |
| 蛋白质和多肽类药物的聚乙二醇结合物—一种新型给药系统;印春华等;《中国药学杂志》;20010531;第36卷(第5期);292-296 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102573917B (zh) | 聚乙二醇化的l-天冬酰胺酶 | |
| EP2451486B1 (en) | Pegylated l-asparaginase | |
| US11802279B2 (en) | Modified L-asparaginase | |
| EP3642340B1 (en) | Modified l-asparaginase | |
| JP2024069234A (ja) | アスパラギナーゼを用いた治療法 | |
| EP3418383A1 (en) | Modified l-asparaginase | |
| WO2016106941A1 (zh) | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 | |
| HK1173092B (en) | Pegylated l-asparaginase | |
| HK40090811A (en) | Modified l-asparaginase | |
| HK40029594A (en) | Modified l-asparaginase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1173092 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1173092 Country of ref document: HK |